Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sponsor:
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Center for Research Resources (NCRR)
Juvenile Diabetes Research Foundation
American Diabetes Association
Information provided by (Responsible Party):
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier:
NCT01030861
First received: December 11, 2009
Last updated: April 7, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2022
  Estimated Primary Completion Date: January 2021 (Final data collection date for primary outcome measure)